We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca PLC sought to reassure investors Thursday that its existing products can underpin earnings growth while the drugmaker
replenishes its thin pipeline of future drugs.
Predix Pharmaceuticals, based in Israel and Lexington, Mass., has begun Phase I clinical trials of a new drug, PRX-07034, for the treatment of obesity and cognitive impairment (associated with Alzheimer's disease or schizophrenia).
New York-based Axonyx and TorreyPines, headquartered in La Jolla, Calif., have entered into a definitive merger agreement to create a new biopharmaceutical company that discovers and develops treatments for central nervous system (CNS) disorders.
French drugmaker sanofi pasteur has signed an agreement with U.S.-based Emergent BioSolutions for the worldwide rights to Emergent's proprietary proteins for the development of a novel meningitis B vaccine, the companies announced.
The pharmaceutical industry in Andhra Pradesh did not experience any growth during October 2005-March 2006, according to a survey conducted by the southern region of Confederation of Indian Industry (CII).
Cyntellect, Inc., a privately-held biotechnology company, today announced that it has received a $2.2 million equity purchase milestone payment from Sigma-Aldrich.
Gilead Sciences Inc. said Tuesday it will acquire Canadian subsidiary Raylo Chemicals Inc., along with most of the assets of the specialty chemicals company.
GlaxoSmithKline (GSK) and Galapagos NV announced today the creation of a worldwide, multi-year, multi-programme drug discovery and development alliance in the field of osteoarthritis.